These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 8066074)

  • 1. Is immunoreactivity for p53 useful in distinguishing benign from malignant effusions? Localization of p53 gene product in benign mesothelial and adenocarcinoma cells.
    Walts AE; Said JW; Koeffler HP
    Mod Pathol; 1994 May; 7(4):462-8. PubMed ID: 8066074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of p53 protein in the study of serous effusions.
    Zoppi JA; Pellicer EM; Sundblad AS
    Acta Cytol; 1995; 39(4):721-4. PubMed ID: 7631546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids.
    Schofield K; D'Aquila T; Rimm DL
    Cancer; 1997 Oct; 81(5):293-8. PubMed ID: 9349517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
    Tamboli P; Amin MB; Xu HJ; Linden MD
    Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 immunostaining as a marker of malignancy in cytologic preparations of body fluids.
    Tiniakos DG; Healicon RM; Hair T; Wadehra V; Horne CH; Angus B
    Acta Cytol; 1995; 39(2):171-6. PubMed ID: 7887063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferative activity and p53 over-expression of ovarian epithelial tumors.
    Kuwata T; Kitagawa M; Takemura T; Hirokawa K
    Gen Diagn Pathol; 1995 Oct; 141(2):131-9. PubMed ID: 8548593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Image analysis and flow cytometric DNA studies of benign and malignant body cavity fluids: reappraisal of the role of current methods in the differential diagnosis of reactive versus malignant conditions.
    Lazcano O; Chen LM; Tsai C; Li CY; Katzmann JA; Sebo TJ; Kimlinger TK; Baker J
    Mod Pathol; 2000 Jul; 13(7):788-96. PubMed ID: 10912939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutated p53 protein expression and proliferative activity in advanced gastric cancer.
    Ikeguchi M; Saito H; Kondo A; Tsujitani S; Maeta M; Kaibara N
    Hepatogastroenterology; 1999; 46(28):2648-53. PubMed ID: 10522058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis of p53 overexpression in human colonic tumors.
    Darmon E; Cleary KR; Wargovich MJ
    Cancer Detect Prev; 1994; 18(3):187-95. PubMed ID: 8076381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal cell adenocarcinoma of the salivary glands: comparison with basal cell adenoma through assessment of cell proliferation, apoptosis, and expression of p53 and bcl-2.
    Nagao T; Sugano I; Ishida Y; Hasegawa M; Matsuzaki O; Konno A; Kondo Y; Nagao K
    Cancer; 1998 Feb; 82(3):439-47. PubMed ID: 9452259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of four antibodies in detecting p53 protein for predicting clinicopathological and prognostic significance in colorectal adenocarcinoma.
    Zhang Hong
    Clin Cancer Res; 1999 Dec; 5(12):4126-32. PubMed ID: 10632350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations.
    Hecht JL; Pinkus JL; Pinkus GS
    Cancer; 2006 Feb; 108(1):56-9. PubMed ID: 16329115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenocarcinoma arising in extragonadal endometriosis: an immunohistochemical study.
    Han AC; Hovenden S; Rosenblum NG; Salazar H
    Cancer; 1998 Sep; 83(6):1163-9. PubMed ID: 9740081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.
    Ruitenbeek T; Gouw AS; Poppema S
    Arch Pathol Lab Med; 1994 Mar; 118(3):265-9. PubMed ID: 8135629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
    Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
    Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of p53 protein in benign and malignant laryngeal epithelial lesions.
    Poljak M; Gale N; Kambic V; Ferluga D; Fischinger J
    Anticancer Res; 1996; 16(4A):1947-51. PubMed ID: 8712726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBME-1 immunostaining in reactive mesothelial versus metastatic adenocarcinoma cells in serous fluid.
    Rahmani A; Dehghani MZ; Afshar NM; Heidarian H; Tahririan R
    Indian J Pathol Microbiol; 2011; 54(3):460-3. PubMed ID: 21934203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of p53 immunohistochemical overexpression in ethmoidal mucosa of woodworkers.
    Valente G; Ferrari L; Kerim S; Gervasio CF; Ricci E; Migliaretti G; Pira E; Bussi M
    Cancer Detect Prev; 2004; 28(2):99-106. PubMed ID: 15068833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.